Mitsuo Okubo

Title: Mitsuo Okubo: Innovator in Cancer Research

Introduction

Mitsuo Okubo is a prominent inventor based in Saitama, Japan. He has made significant contributions to the field of cancer research, particularly in the development of cancer-associated antigen analogue peptides. His work aims to enhance the understanding and treatment of ovarian cancer.

Latest Patents

Mitsuo Okubo holds a patent for "Cancer-associated antigen analogue peptides and uses thereof." This patent addresses critical issues in ovarian cancer treatment. The inventors confirmed the presence of ovarian cancer antigen-specific T cells in the peripheral blood of ovarian cancer patients. They utilized an experimental system that detects combinations of CD4 and IL-4 or IFN-γ. The research revealed that antigen-specific CD4-positive T cells are present at an average frequency of about 4% in the peripheral mononuclear cells of both patients and healthy subjects. The inventors analyzed the epitope for T cells in the core protein MUC 16 of the ovarian cancer-associated antigen CA 125, identifying the amino acid sequence FTLNFTITN (SEQ ID NO: 1) as a shorter epitope. Furthermore, they discovered that the analogue peptide OVCA11: GHTAPGPLLVPFTLNFTITN (SEQ ID NO:11) is suitable for T cell activation.

Career Highlights

Mitsuo Okubo is associated with Chugai Seiyaku Kabushiki Kaisha, a leading pharmaceutical company in Japan. His work has been instrumental in advancing cancer immunotherapy and understanding the immune response to ovarian cancer.

Collaborations

Mitsuo Okubo has collaborated with notable colleagues, including Satoru Takeda and Hiroo Maeda. Their combined expertise has contributed to the success of their research and innovations in cancer treatment.

Conclusion

Mitsuo Okubo's innovative work in cancer research, particularly in the development of antigen analogue peptides, showcases his commitment to improving cancer therapies. His contributions are vital in the ongoing fight against ovarian cancer.